Skip to main content

Advertisement

Table 2 Impact of concomitant peripheral arthritis on the treatments received during the 5-year follow-up period in patients with recent onset axial spondyloarthritis

From: Evaluation of concomitant peripheral arthritis in patients with recent onset axial spondyloarthritis: 5-year results from the DESIR cohort

  Any arthritis
n = 255 (%)
No arthritis
n = 453 (%)
p value*
NSAIDs ever 246 (96.5) 435 (96.0) 0.682
TNFb ever 126 (49.4) 132 (29.1) < 0.001
csDMARDs ever 103 (40.4) 63 (13.9) < 0.001
Oral corticosteroids ever 96 (37.6) 100 (22.1) < 0.001
Intramuscular corticosteroids ever 6 (2.4) 3 (0.7) 0.039
Intravenous corticosteroids ever 7 (2.7) 7 (1.5) 0.336
Intraarticular corticosteroid ever 79 (31.0) 31 (6.8) < 0.001
  1. All results are presented as n (%). Percentages indicate number of patients with the covariate from the total number of patients in each category
  2. TNFb TNF blockers, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs
  3. *p value for mixed model with random effects